|

Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines)

ByPsychedelic Spotlight

What’s up Psychedelic Investors? In today’s episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started.

MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Similar Posts

  • This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]

    Listen, Videos

    In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.

    We will cover the latest developments in the field writ large.
    This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

    Timestamps:
    0:00 – Intro
    0:32 – Norway Decriminalization Bill
    1:59 – Psychedelic Market Stats
    3:21 – Magic Mushrooms to Treat Obesity
    5:40 – Ketamine to Treat Suicidal Thoughts?
    7:09 -The Acid King?
    8:58 – MindMed (MMED/MMEDF/MMQ) Updates
    10:04 – Compass Pathways (CMPS) Updates
    11:44 – Atai Life Sciences Updates
    14:02 – Numinus (NUMI) Updates
    15:13 – CYBIN Updates

    So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

  • AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

    Learn, Videos

    AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

    First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

    Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

    Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

    Timestamps:

    0:00 – Intro
    1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
    Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
    3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
    7:29 – Texas House Approves a Psychedelic Research Bill
    9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

    Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
    https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

    Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
    https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

    Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

    Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD